Abstract
BackgroundWith the increasing incidence of papillary thyroid carcinoma (PTC), PTC continues to garner attention worldwide; however its pathogenesis remains to be elucidated. The purpose of this study was to explore key biomarkers and potential new therapeutic targets for, PTC.MethodsGEO2R and Venn online software were used for screening of differentially expressed genes. Hub genes were screened via STRING and Cytoscape, followed by Gene Ontology and KEGG enrichment analysis. Finally, survival analysis and expression validation were performed using the UALCAN online software and immunohistochemistry.ResultsWe identified 334 consistently differentially expressed genes (DEGs) comprising 136 upregulated and 198 downregulated genes. Gene Ontology enrichment analysis results suggested that the DEGs were mainly enriched in cancer-related pathways and functions. PPI network visualization was performed and 17 upregulated and 13 downregulated DEGs were selected. Finally, the expression verification and overall survival analysis conducted using the Gene Expression Profiling Interactive Analysis Tool (GEPIA) and UALCAN showed that LPAR5, TFPI, and ENTPD1 were associated with the development of PTC and the prognosis of PTC patients, and the expression of LPAR5, TFPI and ENTPD1 was verified using a tissue chip.ConclusionsIn summary, the hub genes and pathways identified in the present study not only provide information for the development of new biomarkers for PTC but will also be useful for elucidation of the pathogenesis of PTC.
Highlights
Over the past few years, thyroid diseases have garnered increasing attention and the incidence of thyroid cancer has markedly increased [1]
The expression verification and overall survival analysis conducted using the Gene Expression Profiling Interactive Analysis Tool (GEPIA) and UALCAN showed that Lysophosphatidic acid receptor 5 (LPAR5), Tissue factor pathway inhibitor (TFPI), and Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) were associated with the development of papillary thyroid cancer (PTC) and the prognosis of PTC patients, and the expression of LPAR5, TFPI and ENTPD1 was verified using a tissue chip
The hub genes and pathways identified in the present study provide information for the development of new biomarkers for PTC but will be useful for elucidation of the pathogenesis of PTC
Summary
Over the past few years, thyroid diseases have garnered increasing attention and the incidence of thyroid cancer has markedly increased [1]. The early prevention and diagnosis of thyroid cancer remains a necessity and concern for doctors and scientists, and exploration of potential key biomarkers and novel therapeutic targets in PTC is imperative for doctors and patients alike. With the large-scale application of high-throughput screening technology, we have identified several novel genes associated with disease initiation and progression and have achieved a comprehensive understanding of the molecular mechanisms of development of various tumors [5,6,7,8]. The integrated analysis provided insights for the development of new biomarkers for PTC, which may be valuable for conducting further research into the mechanisms of PTC as well as for use in clinical applications in diagnosis, prognosis, and therapy. The purpose of this study was to explore key biomarkers and potential new therapeutic targets for, PTC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
